Abstract
Background: Tailored recommendation for adjuvant chemotherapy in breast cancer patients is of great importance. Gene signatures, such as the 70-gene signature (MammaPrint®), have shown to provide additional prognostic information and are used to refine risk estimations and adjuvant chemotherapy recommendations for individual patients, and have been incorporated in international guidelines. This survey assessed agreement among oncologists on risk assessment and chemotherapy recommendation, the impact of adding the 70-gene signature result to clinical-pathological characteristics, and changes over time.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
